Latest news with #Non-HodgkinLymphoma
Yahoo
2 days ago
- Sport
- Yahoo
Scottie Scheffler deletes Venmo account in latest incident of bettors harassing an athlete
Scottie Scheffler signs autographs during a practice round ahead of the U.S. Open golf tournament at Oakmont Country Club. (Carolyn Kaster / Associated Press) That Scottie Scheffler is the prohibitive favorite to win the U.S. Open this week at historic Oakmont Country Club surprises no one. He's the top-ranked golfer in the world, winning three of his last four starts, including the PGA Championship. That Scheffler deleted his Venmo account because bettors continually clicked the pay/request link on the mobile payment app and rudely demanded that he reimburse them when he didn't win probably shouldn't surprise anyone, either. Advertisement "I think everybody hears from fans whether they have a financial benefit or anything in their outcome," Scheffler told reporters at the U.S. Open on Tuesday. "That's why I had to get rid of my Venmo, because I was either getting paid by people or people requesting me a bunch of money when I didn't win. It wasn't a good feeling." Scheffler chuckled nervously when he said it, but athletes getting harassed by folks who lost money betting on their performances isn't a laughing matter. Read more: Scottie Scheffler triumphs in PGA Championship for his third major title Ever since the U.S. Supreme Court in 2018 struck down a federal law that had prohibited most states from allowing sports betting, abuse toward athletes from bettors who blame them for their financial losses has soared. Gambling on sports is now legal in 39 states. Advertisement Houston Astros pitcher Lance McCullers Jr. and Boston Red Sox pitcher Liam Hendriks said recently that their families have received death threats on social media. A man who lost money May 10 when McCullers gave up seven runs while recording only one out in a loss to the Cincinnati Reds threatened to "murder" McCullers' two young daughters. Police traced the threats to an intoxicated man overseas who had lost money betting on the game. "I understand people are very passionate and people love the Astros and love sports, but threatening to find my kids and murder them is a little bit tough to deal with," McCullers said in an understatement. "There have been many, many threats over the years aimed at me mostly ... but I think bringing kids into the equation, threatening to find them or next time they see us in public they're going to stab my kids to death. Things like that are tough to hear as a dad." Hendriks posted on his Instagram story that he has received death threats while struggling to regain his form after missing nearly two years because of Non-Hodgkin Lymphoma and Tommy John surgery. Advertisement 'Threats against my life and my wife's life are horrible and cruel,' Hendriks wrote. 'You need help. Comments telling me to commit suicide and how you wish I died from cancer are disgusting and vile. Maybe you should take a step back and re-evaluate your life's purpose before hiding behind a screen attacking players and their families. Read more: Pete Rose, 'Shoeless' Joe Jackson reinstated by Major League Baseball, making Hall of Fame election possible Hendriks later explained to reporters why he responded on social media. 'With the rise of sports gambling, it's gotten a lot worse,' he said. 'Unfortunately, that tends to be what it ends up being — whether it be Venmo requests, whether it be people telling you in their comments, 'Hey, you blew my parlay. Go [f—-] yourself,' kind of stuff." Advertisement Some gamblers believe they can impact the outcomes of competition through harassment. FanDuel banned a man in Philadelphia after he bragged on social media about intimidating three-time Olympic gold medalist Gabby Thomas at a Grand Slam Track meet two weeks ago. 'I made Gabby lose by heckling her. And it made my parlay win,' he wrote on a post that included a screenshot of two bets on FanDuel. Thomas responded by posting, "This grown man followed me around the track as I took pictures and signed autographs for fans (mostly children) shouting personal insults — anybody who enables him online is gross." College athletes are also targets, especially during high-volume betting events such as March Madness and the College Football Playoff. Advertisement The NCAA is lobbying for states to ban proposition bets on the performances of individual college athletes, saying it creates a temptation to compromise game integrity. Read more: Q&A: How are college sports changing in the wake of House settlement? College athletes have long been considered more susceptible to taking money from gamblers than pro athletes because they are amateurs. That will soon change because of the passage last week of the House settlement, a revenue-sharing model that will allow universities to directly pay athletes up to $20.5 million per year. Not to say paying college athletes will insulate them from disgruntled gamblers. The NCAA will continue to press for laws that could ban bettors from state-licensed sportsbooks if they are found guilty of harassment. The sheer volume of betting makes policing the harassment and intimidation of athletes an enormous challenge. This year, it was estimated that $3 billion was legally wagered on the men's and women's NCAA basketball tournaments, according to the American Gaming Association (AGA), an increase of about 10% from 2024. Advertisement In an attempt to be proactive about harassment ahead of March Madness, the NCAA posted a public service announcement video titled "Don't Be a Loser." "There's losing and then there's being a loser. Game time comes with enough pressure," the video said. "Way too often, people are betting on sports, losing, and taking it out on the athletes. Only a loser would harass college athletes after losing a bet, but it happens almost every day. "Root for your team, get crazy when the buzzer sounds, but don't harass anyone because you lost a bet. It's time we draw the line and put an end to the abuse." Scheffler drew the line by deleting his Venmo account, which had become just another means for gamblers to communicate with a prominent athlete. His career earnings exceed $150 million, according to Spotrac, but he said a handful of bettors had paid him 'maybe a couple bucks here or there' via Venmo after he won tournaments and presumably lined their pockets as well. Advertisement 'That didn't happen nearly as much as the requests did,' Scheffler added. Get the best, most interesting and strangest stories of the day from the L.A. sports scene and beyond from our newsletter The Sports Report. This story originally appeared in Los Angeles Times.
Los Angeles Times
2 days ago
- Sport
- Los Angeles Times
Scottie Scheffler deletes Venmo account in latest incident of bettors harassing an athlete
That Scottie Scheffler is the prohibitive favorite to win the U.S. Open this week at historic Oakmont Country Club surprises no one. He's the top-ranked golfer in the world, winning three of his last four starts, including the PGA Championship. That Scheffler deleted his Venmo account because bettors continually clicked the pay/request link on the mobile payment app and rudely demanded that he reimburse them when he didn't win probably shouldn't surprise anyone, either. 'I think everybody hears from fans whether they have a financial benefit or anything in their outcome,' Scheffler told reporters at the U.S. Open on Tuesday. 'That's why I had to get rid of my Venmo, because I was either getting paid by people or people requesting me a bunch of money when I didn't win. It wasn't a good feeling.' Scheffler chuckled nervously when he said it, but athletes getting harassed by folks who lost money betting on their performances isn't a laughing matter. Ever since the U.S. Supreme Court in 2018 struck down a federal law that had prohibited most states from allowing sports betting, abuse toward athletes from bettors who blame them for their financial losses has soared. Gambling on sports is now legal in 39 states. Houston Astros pitcher Lance McCullers Jr. and Boston Red Sox pitcher Liam Hendriks said recently that their families have received death threats on social media. A man who lost money May 10 when McCullers gave up seven runs while recording only one out in a loss to the Cincinnati Reds threatened to 'murder' McCullers' two young daughters. Police traced the threats to an intoxicated man overseas who had lost money betting on the game. 'I understand people are very passionate and people love the Astros and love sports, but threatening to find my kids and murder them is a little bit tough to deal with,' McCullers said in an understatement. 'There have been many, many threats over the years aimed at me mostly ... but I think bringing kids into the equation, threatening to find them or next time they see us in public they're going to stab my kids to death. Things like that are tough to hear as a dad.' Hendriks posted on his Instagram story that he has received death threats while struggling to regain his form after missing nearly two years because of Non-Hodgkin Lymphoma and Tommy John surgery. 'Threats against my life and my wife's life are horrible and cruel,' Hendriks wrote. 'You need help. Comments telling me to commit suicide and how you wish I died from cancer are disgusting and vile. Maybe you should take a step back and re-evaluate your life's purpose before hiding behind a screen attacking players and their families. Hendriks later explained to reporters why he responded on social media. 'With the rise of sports gambling, it's gotten a lot worse,' he said. 'Unfortunately, that tends to be what it ends up being — whether it be Venmo requests, whether it be people telling you in their comments, 'Hey, you blew my parlay. Go [f—-] yourself,' kind of stuff.' Some gamblers believe they can impact the outcomes of competition through harassment. FanDuel banned a man in Philadelphia after he bragged on social media about intimidating three-time Olympic gold medalist Gabby Thomas at a Grand Slam Track meet two weeks ago. 'I made Gabby lose by heckling her. And it made my parlay win,' he wrote on a post that included a screenshot of two bets on FanDuel. Thomas responded by posting, 'This grown man followed me around the track as I took pictures and signed autographs for fans (mostly children) shouting personal insults — anybody who enables him online is gross.' College athletes are also targets, especially during high-volume betting events such as March Madness and the College Football Playoff. The NCAA is lobbying for states to ban proposition bets on the performances of individual college athletes, saying it creates a temptation to compromise game integrity. College athletes have long been considered more susceptible to taking money from gamblers than pro athletes because they are amateurs. That will soon change because of the passage last week of the House settlement, a revenue-sharing model that will allow universities to directly pay athletes up to $20.5 million per year. Not to say paying college athletes will insulate them from disgruntled gamblers. The NCAA will continue to press for laws that could ban bettors from state-licensed sportsbooks if they are found guilty of harassment. The sheer volume of betting makes policing the harassment and intimidation of athletes an enormous challenge. This year, it was estimated that $3 billion was legally wagered on the men's and women's NCAA basketball tournaments, according to the American Gaming Association (AGA), an increase of about 10% from 2024. In an attempt to be proactive about harassment ahead of March Madness, the NCAA posted a public service announcement video titled 'Don't Be a Loser.' 'There's losing and then there's being a loser. Game time comes with enough pressure,' the video said. 'Way too often, people are betting on sports, losing, and taking it out on the athletes. Only a loser would harass college athletes after losing a bet, but it happens almost every day. 'Root for your team, get crazy when the buzzer sounds, but don't harass anyone because you lost a bet. It's time we draw the line and put an end to the abuse.' Scheffler drew the line by deleting his Venmo account, which had become just another means for gamblers to communicate with a prominent athlete. His career earnings exceed $150 million, according to Spotrac, but he said a handful of bettors had paid him 'maybe a couple bucks here or there' via Venmo after he won tournaments and presumably lined their pockets as well. 'That didn't happen nearly as much as the requests did,' Scheffler added.
Globe and Mail
26-03-2025
- Business
- Globe and Mail
Non-Hodgkin's Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Non-Hodgkin Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin's Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin's Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Non-Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-Hodgkin's Lymphoma Pipeline Outlook Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report In March 2025, Hoffmann-La Roche conducted a phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma. In March 2025, Bristol-Myers Squibb organized a phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma. DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working to develop 220+ pipeline therapies for Non-Hodgkin Lymphoma treatment. The leading Non-Hodgkin Lymphoma Companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others. Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others. Stay ahead with the most recent pipeline outlook for Non-Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Hodgkin's Lymphoma Treatment Drugs Non-Hodgkin Lymphoma Emerging Drugs Profile Mosunetuzumab: Hoffmann-la Roche Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. Mosunetuzumab is equipped with structural features that promote T-cell recruitment and retention, resulting in an antitumor effect. In preclinical models, mosunetuzumab induced T-cell proliferation and B-cell death; furthermore, efficient B-cell killing was achieved at low effector-to-target (T cell:B cell) ratios. Use of mosunetuzumab in combination with PD-L1 inhibition may address adaptive immune resistance mechanisms to enhance anticancer activity against B-cell malignancies. The drug is being evaluated in Phase III Study to evaluate the efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive b-cell Non-Hodgkin's Lymphoma. Tisagenlecleucel: Novartis Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient's T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR is comprised of a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains from 4-1BB (CD137) and CD3 zeta Label. These intracellular costimulatory signaling domains increase the expansion, longer-term persistence and potency of CAR T cells: the CD3 zeta component is critical for initiating T-cell activation and antitumor activity, while 4-1BB enhances the expansion and persistence of tisagenlecleucel {FDA Label, A20379]. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma. Capivasertib: AstraZeneca Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma. BI-1206: BioInvent BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin's lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients. HMPL-760: Hutchmed HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors. The Non-Hodgkin's Lymphoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin's Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin's Lymphoma Treatment. Non-Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Non-Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin's Lymphoma market Explore groundbreaking therapies and clinical trials in the Non-Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Non-Hodgkin's Lymphoma Drugs Non-Hodgkin's Lymphoma Companies Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences Inc. and others. Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral intravenous Subcutaneous Topical Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Non-Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-Hodgkin's Lymphoma Market Drivers and Barriers Scope of the Non-Hodgkin Lymphoma Pipeline Report Coverage- Global Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others. Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others. Get the latest on Non-Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-Hodgkin's Lymphoma Companies, Key Products and Unmet Needs Table of Content Introduction Non-Hodgkin's Lymphoma Executive Summary Non-Hodgkin Lymphoma: Overview Non-Hodgkin's Lymphoma Pipeline Therapeutics Non-Hodgkin's Lymphoma Therapeutic Assessment Non-Hodgkin Lymphoma – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Tisagenlecleucel: Novartis Drug profiles in the detailed report….. Mid Stage Products (Phase II) Capivasertib: AstraZeneca Drug profiles in the detailed report….. Early Stage Products (Phase I/II) BI-1206: BioInvent Drug profiles in the detailed report….. Early Stage Products (Phase I) HMPL-760: Hutchmed Drug profiles in the detailed report….. Preclinical Stage Products Product Name: Company Name Drug profiles in the detailed report….. Inactive Products Non-Hodgkin Lymphoma Key Companies Non-Hodgkin Lymphoma Key Products Non-Hodgkin Lymphoma- Unmet Needs Non-Hodgkin Lymphoma- Market Drivers and Barriers Non-Hodgkin Lymphoma- Future Perspectives and Conclusion Non-Hodgkin Lymphoma Analyst Views Non-Hodgkin Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
